The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who have undergone K4Care testing
Pathological and imaging confirmation of metastatic or progressive stage IV cancer.
Consent to the use of their clinical data.
Diagnosis of one of the following common solid tumor types: lung, colorectal, breast, gastric, or cancer of unknown primary origin.
Prior K4Care testing to identify tumor tissue (FFPE) mutations and consent to the use of their sequencing data.
Refusal to participate in the study.
Absence of prior K4Care testing.
Diagnosis of early-stage cancer or hematologic malignancy.
Refusal to provide clinical information or blood samples.
Gene Solutions
Lead sponsor
The Medical Genetics Institute (MGI) of HCMC
Collaborator